Shares of NGM Biopharmaceuticals are up 60c or up almost 12% to $5.65 per share in after hours trading after after holder Column Group buys $1.5M in shares. Beneficial owner of NGM Biopharmaceuticals Column Group, disclosed in a regulatory filing that it had purchased 309,070 shares of company stock at $4.79 per share between January 10 and January 11 for a total transaction amount of $1,479,364.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NGM:
- NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
- NGM Biopharmaceuticals outlines 2023 corporate priorities
- NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
- NGM Biopharmaceuticals announces presentation on NGM936 at ASH
- NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting